• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Simeprevir capsules.西米普明胶囊。
Hosp Pharm. 2014 Apr;49(4):376-89. doi: 10.1310/hpj4904-376.
2
Dolutegravir.多替拉韦
Hosp Pharm. 2014 Feb;49(2):184-95. doi: 10.1310/hpj4902-184.
3
Dimethyl fumarate.富马酸二甲酯
Hosp Pharm. 2013 Sep;48(8):668-79. doi: 10.1310/hpj4808-668.
4
Dapagliflozin.达格列净
Hosp Pharm. 2014 Jul;49(7):647-62. doi: 10.1310/hpj4907-647.
5
Perampanel.吡仑帕奈
Hosp Pharm. 2013 Apr;48(4):321-31. doi: 10.1310/hpj4804-321.
6
Tedizolid phosphate.磷酸泰地唑胺
Hosp Pharm. 2014 Nov;49(10):961-71. doi: 10.1310/hpj4910-961.
7
Apixaban.阿哌沙班
Hosp Pharm. 2013 Jun;48(6):494-509. doi: 10.1310/hpj4806-494.
8
Sofosbuvir.索磷布韦
Hosp Pharm. 2014 May;49(5):466-78. doi: 10.1310/hpj4905-466.
9
Alogliptin.阿格列汀
Hosp Pharm. 2013 Jul;48(7):580-92. doi: 10.1310/hpj4807-580.
10
Teriflunomide.特立氟胺
Hosp Pharm. 2013 Mar;48(3):231-40. doi: 10.1310/hpj4803-231.

本文引用的文献

1
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.西美瑞韦提高了治疗经验丰富的 HCV 基因 1 型感染患者持续病毒学应答率:一项 IIb 期试验。
Gastroenterology. 2014 Feb;146(2):430-41.e6. doi: 10.1053/j.gastro.2013.10.058. Epub 2013 Nov 1.
2
Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.在日本,初治的丙型肝炎基因型 1 感染患者接受每日一次simeprevir(TMC435)联合聚乙二醇干扰素/利巴韦林治疗:DRAGON 研究。
J Gastroenterol. 2014 Jan;49(1):138-47. doi: 10.1007/s00535-013-0875-1. Epub 2013 Sep 5.
3
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.替比夫定联合聚乙二醇干扰素α-2a 和利巴韦林治疗慢性乙型肝炎的疗效和安全性:随机、双盲、安慰剂对照的Ⅲ期临床研究。
Hepatology. 2013 Dec;58(6):1918-29. doi: 10.1002/hep.26641. Epub 2013 Oct 11.
4
Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).TMC435 单药治疗(研究 TMC435-C202)患者中 HCV 基因型 2-6 的病毒学应答和特征。
J Hepatol. 2013 Mar;58(3):445-51. doi: 10.1016/j.jhep.2012.10.028. Epub 2012 Nov 7.
5
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study.TMC435 单药治疗感染 HCV 基因型 2-6 患者的抗病毒活性:TMC435-C202,一项 IIa 期、开放性研究。
J Hepatol. 2012 Jun;56(6):1247-53. doi: 10.1016/j.jhep.2011.12.033. Epub 2012 Feb 10.
6
Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.丙型肝炎1型患者每日一次服用TMC435联合聚乙二醇干扰素/利巴韦林的快速病毒反应:一项随机试验。
Antivir Ther. 2011;16(7):1021-33. doi: 10.3851/IMP1894.
7
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.1型慢性丙型肝炎病毒感染治疗的最新进展:美国肝病研究协会2011年实践指南
Hepatology. 2011 Oct;54(4):1433-44. doi: 10.1002/hep.24641. Epub 2011 Sep 26.
8
Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.每日一次 TMC435 治疗:健康志愿者和丙型肝炎患者中的 I 期研究显示 HCV-RNA 迅速下降。
Gastroenterology. 2010 Mar;138(3):913-21. doi: 10.1053/j.gastro.2009.10.033. Epub 2009 Oct 21.

西米普明胶囊。

Simeprevir capsules.

作者信息

Cada Dennis J, Levien Terri L, Baker Danial E

机构信息

Founder and Contributing Editor, The Formulary, Washington State University , Spokane, Washington.

Clinical Associate Professor of Pharmacotherapy, Drug Information Center, Washington State University , Spokane, Washington.

出版信息

Hosp Pharm. 2014 Apr;49(4):376-89. doi: 10.1310/hpj4904-376.

DOI:10.1310/hpj4904-376
PMID:24958945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4062751/
Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The April 2014 monograph topics are dapagliflozin, tasimelteon, treprostinil diolamine, avarofloxacin, and idelalisib. The DUE/MUE is on dapagliflozin.

摘要

每月,《处方集专论服务》的订阅者会收到5至6篇关于新发布或处于3期临床试验后期阶段药物的详细记录专论。这些专论面向药学与治疗学委员会。订阅者每月还会收到关于对议程以及药房/护理在职培训有用药物的1页摘要专论。每月还会提供一份全面的目标药物利用评估/用药评估(DUE/MUE)。订阅后,专论会以印刷版形式发送,也可在线获取。专论可根据机构需求进行定制。现在每月会随《处方集专论服务》发布一份药物类别综述。通过《处方集》的合作,《医院药学》在本专栏发表精选综述。如需了解更多关于《处方集专论服务》的信息,请致电《处方集》800 - 322 - 4349。2014年4月的专论主题为达格列净、他司美琼、曲前列尼尔二乙醇胺、阿伐沙星和依地那利昔布。DUE/MUE是关于达格列净的。